UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | ||||
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) | October 8, 2004 |
SALIX PHARMACEUTICALS, LTD. |
(Exact name of registrant as specified in its charter) |
Delaware | 000-23265 | 94-3267443 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina | 27615 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code | (919) 862-1000 |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On October 8, 2004, Salix Pharmaceuticals, Ltd. issued a press release announcing plans to host a conference call. A copy of this press release is attached.
Item 9.01. Financial Statements and Exhibits.
(c) | Exhibits |
Exhibit No. | Description | |
99.1 | Press release dated October 8, 2004. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
SALIX PHARMACEUTICALS, LTD.
| ||
Date: October 8, 2004 | ||
/s/ Adam C. Derbyshire | ||
Adam C. Derbyshire | ||
Senior Vice President and Chief Financial Officer |